COVID-19 DRUGS-Investigational treatment

June 2021
Vol-7, Issue-3
Paper ID: 14635
ISSN: 2395-4396
Downloads: 0

Abstract & Details

Research Area
Pharmacy
Keywords
Drug profile efficacy clinical research metabolism interactions drug-receptor inflammatory response immune complexes
Abstract
COVID-19 is the disease caused by an infection of the SARS-CoV-2 virus, first identified in the city of Wuhan, in China's Hubei province in December 2019. COVID-19 was previously known as 2019 Novel Coronavirus (2019-nCoV) respiratory disease before the World Health Organization (WHO) declared the official name as COVID-19 in February 2020.The SARS-CoV-2 virus belongs to the family of viruses called coronaviruses, which also includes the viruses that cause the common cold, and the viruses that cause more serious infections such as severe acute respiratory syndrome (SARS), which was caused by SARS-CoV in 2002, and Middle East respiratory syndrome (MERS), which was caused by MERS-CoV in 2012. Like the other coronaviruses, the SARS-CoV-2 virus primarily causes respiratory tract infections, and the severity of the COVID-19 disease can range from mild to fatal. Serious illness from the infection is caused by the onset of pneumonia and acute respiratory distress syndrome (ARDS). Currently, there are no FDA approved treatments for COVID-19, and the development of vaccines are still in pipeline.
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Author Information

# Name Institute / Affiliation
1 DARISHETTI HARITH KUMAR St.Peter’s Institute of Pharmaceutical Science,Hanmakonda,Warangal,Telangana,India.
2 NALLALA SANDHYA St.Peter’s Institute of Pharmaceutical Science,Hanmakonda,Warangal,Telangana,India.
3 RAFIKUL HOQUE St.Peter’s Institute of Pharmaceutical Science,Hanmakonda,Warangal,Telangana,India.
4 LUIT AZHAR ALI St.Peter’s Institute of Pharmaceutical Science,Hanmakonda,Warangal,Telangana,India.

How to Cite

Use the following formats to cite this article in your research.

APA Style
KUMAR, DARISHETTI HARITH, SANDHYA, NALLALA, HOQUE, RAFIKUL, & ALI, LUIT AZHAR (2021). COVID-19 DRUGS-Investigational treatment. International Journal of Advance Research and Innovative Ideas In Education, 7(3), 2501-2510.
MLA Style
KUMAR, DARISHETTI HARITH, et al. "COVID-19 DRUGS-Investigational treatment." International Journal of Advance Research and Innovative Ideas In Education, vol. 7, no. 3, 2021, pp. 2501-2510.
IEEE Style
DARISHETTI HARITH KUMAR, NALLALA SANDHYA, RAFIKUL HOQUE, and LUIT AZHAR ALI, "COVID-19 DRUGS-Investigational treatment," International Journal of Advance Research and Innovative Ideas In Education, vol. 7, no. 3, pp. 2501-2510, 2021.
Vancouver Style
KUMAR DARISHETTI HARITH, SANDHYA NALLALA, HOQUE RAFIKUL, ALI LUIT AZHAR. COVID-19 DRUGS-Investigational treatment. International Journal of Advance Research and Innovative Ideas In Education. 2021;7(3):2501-2510.
Harvard Style
KUMAR, DARISHETTI HARITH, SANDHYA, NALLALA, HOQUE, RAFIKUL, & ALI, LUIT AZHAR (2021) 'COVID-19 DRUGS-Investigational treatment', International Journal of Advance Research and Innovative Ideas In Education, 7(3), pp. 2501-2510.
Chicago Style
KUMAR, DARISHETTI HARITH, et al. "COVID-19 DRUGS-Investigational treatment." International Journal of Advance Research and Innovative Ideas In Education 7, no. 3 (2021): 2501-2510.
Turabian Style
KUMAR, DARISHETTI HARITH, et al. "COVID-19 DRUGS-Investigational treatment." International Journal of Advance Research and Innovative Ideas In Education 7, no. 3 (2021): 2501-2510.

Export Citation